J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-anal
| Current Price | ₹2,224.00 |
|---|---|
| Market Cap | ₹35,258 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 49.4 |
| Return on Equity | 18.69% |
| 52-Week Range | ₹1,603.50 – ₹2,300.00 |
| Beta (1Y) | 0.3 |
| Dividend Yield | 0.85% |
1. Pharmaceuticals-100%
J.B.Chemicals & Pharmaceuticals Ltd. is trading at ₹2,224.00, with a market capitalisation of ₹35,258 Cr.
J.B.Chemicals & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
J.B.Chemicals & Pharmaceuticals Ltd. has a P/E of 49.4 and a return on equity of 18.69%.